Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps.
Ontology highlight
ABSTRACT: Interleukin-2 (IL-2) regulates lymphocyte function by signaling through heterodimerization of the IL-2R? and ?c receptor subunits. IL-2 is of considerable therapeutic interest, but harnessing its actions in a controllable manner remains a challenge. Previously, we have engineered an IL-2 "superkine" with enhanced affinity for IL-2R?. Here, we describe next-generation IL-2 variants that function as "receptor signaling clamps." They retained high affinity for IL-2R?, inhibiting binding of endogenous IL-2, but their interaction with ?c was weakened, attenuating IL-2R?-?c heterodimerization. These IL-2 analogs acted as partial agonists and differentially affected lymphocytes poised at distinct activation thresholds. Moreover, one variant, H9-RETR, antagonized IL-2 and IL-15 better than blocking antibodies against IL-2R? or IL-2R?. Furthermore, this mutein prolonged survival in a model of graft-versus-host disease and blocked spontaneous proliferation of smoldering adult T cell leukemia (ATL) T cells. This receptor-clamping approach might be a general mechanism-based strategy for engineering cytokine partial agonists for therapeutic immunomodulation.
SUBMITTER: Mitra S
PROVIDER: S-EPMC4560365 | biostudies-literature | 2015 May
REPOSITORIES: biostudies-literature
ACCESS DATA